BridgeBio Oncology Therapeutics (BBOT) Enters into Business Combination Agreement with Helix Acquisition Corp. II to Develop RAS and PI3Kα-Targeting Drugs

Shots: BBOT will reverse merge with Helix in a SPAC transaction, where combined entity - "BBOT” will be listed on Nasdaq; closing expected in Q3’25 Upon closing, BBOT will have ~$550M cash (pre-transaction) incl. $100M in existing cash, $196M from Helix’s trust & $260M from PIPE financing. At $10.36/share, the combined entity's implied pro…

ByRidhi RastogiMarch 3, 2025

News

The US FDA Grants Fast Track Designation to BridgeBio Oncology Therapeutics’ BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer

Shots: The US FDA has granted FTD to BBO-8520 for the treatment of metastatic NSCLC with KRAS^G12C mutations in adults BBO-8520 showed significant tumor inhibition in preclinical models, post resistance to sotorasib. In addition, BBO-8520 is being assessed in a P-I (ONKORAS-101) trial in KRAS^G12C NSCLC patients either receiving KRAS^G12C inhibitors or no targeted…

ByDipanshu DixitJanuary 14, 2025

BridgeBio Oncology Therapeutics (BBOT) Enters into Business Combination Agreement with Helix Acquisition Corp. II to Develop RAS and PI3Kα-Targeting Drugs

The US FDA Grants Fast Track Designation to BridgeBio Oncology Therapeutics’ BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer

Contact US

FOLLW US

BridgeBio Oncology Therapeutics (BBOT) Enters into Business Combination Agreement with Helix Acquisition Corp. II to Develop RAS and PI3Kα-Targeting Drugs

The US FDA Grants Fast Track Designation to BridgeBio Oncology Therapeutics’ BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer

FOLLW US

Sign Up to Our Newsletter